Our purpose
Millions of patients suffer from chronic bacterial infections - where antibiotics can only suppress the disease but not cure. At PhagoMed we develop a new generation of precision anti-bacterials that eliminate the pathogen while leaving the microbiome intact. Using our synthetic biology platform, we can design targeted interventions as breakthrough therapies for chronic bacterial infections.
Our lead program PM-477:
Bacterial vaginosis (BV)
Recurrent bacterial vaginosis affects 100 million women across the globe. Today’s therapy relies on long-term suppressive antibiotics that fail to provide a cure. Our engineered lysin works where antibiotics fail and is precise, making it a highly innovative solution.
Are you suffering from BV?
At PhagoMed, we are working to design the best possible therapies for bacterial vaginosis. If you are willing to share your experience with bacterial vaginosis, please click on the link below to complete the survey.
About lysins and phages
Phages have been around since the earliest days of evolution. Phages are natural viruses that hunt and infect bacteria. They then use lysins to break open the cell wall and kill the bacteria.
PhagoMed is member of
PhagoMed is supported by
Latest News
